| 151 |
15610240 | Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. | 2005 Jan |
2 |
| 152 |
15644863 | Angiotensin II-mediated calcium signals and mitogenesis in human prostate stromal cell line hPCPs. | 2005 Jan |
2 |
| 153 |
15680481 | Protein kinase C-mediated inhibition of renal Ca2+ ATPase by physiological concentrations of angiotensin II is reversed by AT1- and AT2-receptor antagonists. | 2005 Apr 15 |
2 |
| 154 |
15718497 | Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. | 2005 Apr 1 |
1 |
| 155 |
15749161 | Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. | 2005 Mar |
1 |
| 156 |
15761243 | Effect of high glucose on superoxide in human mesangial cells: role of angiotensin II. | 2005 |
3 |
| 157 |
15802347 | Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice. | 2005 Apr |
1 |
| 158 |
15872078 | Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. | 2005 Jun |
1 |
| 159 |
15892281 | [Effect of danshensu and ligustrazine on related genes of myocardial hypertrophy induced by angiotensin II]. | 2005 Apr |
1 |
| 160 |
16029066 | Clinical pharmacokinetics of losartan. | 2005 |
1 |
| 161 |
16036315 | Pregnancy and ovarian steroid regulation of angiotensin II type 1 and type 2 receptor expression in ovine uterine artery endothelium and vascular smooth muscle. | 2005 Jan-Apr |
1 |
| 162 |
16082528 | Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. | 2005 Oct |
1 |
| 163 |
16103692 | Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner. | 2005 Sep-Oct |
1 |
| 164 |
16128369 | Long-term combined therapy with losartan and an angiotensin-converting enzyme inhibitor improves functional capacity in patients with left ventricular dysfunction. | 2005 Aug |
1 |
| 165 |
16187699 | The impact of losartan on the lifetime incidence of ESRD and costs in Mexico. | 2005 May-Jun |
2 |
| 166 |
16221106 | Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective. | 2005 Oct |
1 |
| 167 |
16304626 | Effects of intracerebroventricular losartan on angiotensin II-mediated pressor responses and c-fos expression in near-term ovine fetus. | 2005 Dec 26 |
1 |
| 168 |
16321381 | Effects of losartan and irbesartan administration on brain angiotensinogen mRNA levels. | 2005 Dec 28 |
1 |
| 169 |
16336582 | Anemia management and chronic renal failure progression. | 2005 Dec |
1 |
| 170 |
19804143 | Losartan in cardiovascular disease. | 2005 Jul |
2 |
| 171 |
24678070 | Effects of Losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom. | 2005 Nov |
1 |
| 172 |
12754187 | Angiotensin II and the fibroproliferative response to acute lung injury. | 2004 Jan |
1 |
| 173 |
14643897 | Prophylactic and therapeutic treatments with AT 1 and AT 2 receptor antagonists and their effects on changes in the severity of pancreatitis. | 2004 Feb |
1 |
| 174 |
14976148 | Transactivation of the insulin-like growth factor-I receptor by angiotensin II mediates downstream signaling from the angiotensin II type 1 receptor to phosphatidylinositol 3-kinase. | 2004 Jun |
1 |
| 175 |
14999200 | Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy. | 2004 Mar |
1 |
| 176 |
15044323 | Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. | 2004 May 14 |
1 |
| 177 |
15046234 | Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. | 2004 Feb |
1 |
| 178 |
15047641 | Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. | 2004 Apr |
1 |
| 179 |
15129230 | Losartan, an angiotensin II (AT1) receptor antagonist, preserves cerebral blood flow in hypertensive patients with a history of stroke. | 2004 Oct |
2 |
| 180 |
15149345 | Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. | 2004 Jun |
1 |
| 181 |
15152291 | Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. | 2004 May 1 |
2 |
| 182 |
15155270 | Angiotensin II stimulates nitric oxide production in pulmonary artery endothelium via the type 2 receptor. | 2004 Sep |
1 |
| 183 |
15194475 | Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension. | 2004 Jul 1 |
2 |
| 184 |
15203251 | Differential response of human cardiac fibroblasts to angiotensin I and angiotensin II. | 2004 Jun |
1 |
| 185 |
15223728 | Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. | 2004 |
1 |
| 186 |
15225108 | Losartan in diabetic nephropathy. | 2004 Jul |
2 |
| 187 |
15322693 | Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats. | 2004 Aug 25 |
1 |
| 188 |
15361886 | Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment. | 2004 Dec |
3 |
| 189 |
15369420 | Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control. | 2004 Sep |
2 |
| 190 |
15485403 | Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. | 2004 Nov |
1 |
| 191 |
15500378 | Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. | 2004 Nov |
2 |
| 192 |
15530425 | ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. | 2004 Dec 10 |
1 |
| 193 |
15537480 | The role of angiotensin antagonism in stroke prevention in patients with hypertension: focus on losartan. | 2004 Nov |
3 |
| 194 |
15701209 | Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL. | 2004 Dec |
1 |
| 195 |
15803435 | Angiotensin II stimulates arachidonic acid release from bone marrow stromal cells. | 2004 Dec |
1 |
| 196 |
12504053 | Successful treatment of radiation nephropathy with angiotensin II blockade. | 2003 Jan 1 |
1 |
| 197 |
12558462 | Losartan in diabetic nephropathy. | 2003 |
2 |
| 198 |
12577767 | [Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective]. | 2003 Jan 18 |
1 |
| 199 |
12595345 | Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. | 2003 Feb 21 |
3 |
| 200 |
12606520 | Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. | 2003 Mar |
1 |